The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give […]
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
Sometimes things in the stem cell world get complicated and this week is no exception with news of Orchard Therapeutics dropping a seemingly life-saving clinical trial. There are hundreds of kids who could possibly benefit. Rotten apple decision from Orchard Therapeutics From David Jensen at California Stem Cell Report we have something of a scoop:
Weekly reads: Orchard punts on life-saving SCID trial, cardioids with cavities, more Read More »
One of my main research interests is in oncodevelopmental factors. These include factors that are important both for normal stem cell biology and development as well as driving cancer when misregulated. One example includes the MYC family of proto-oncogenes. When I was a postdoc I got especially interested in trying to understand the normal role
Weekly reads: oncodevelopmental factors, iPSC cancer vaccine, more Read More »
There are many ways to classify different stem cells. These differences include yours versus someone else’s cells. Another distinct in a clinical sense is what we call an autologous vs allogeneic stem cell transplant. This post is focused on the difference between allogeneic (someone else’s cells) and autologous (your own) stem cell injections. As a
Autologous vs allogeneic: all you need to know on therapy Read More »
Sometimes change takes a very long time, but with brain organoids or advocating for better information for patients at Clinicaltrials.gov, after waiting you can see some interesting developments. These are two of the regenerative medicine stories of the week, along with some striking research papers. Clinicaltrials.gov Some of us have been advocating for improvements at
Regenerative reads: brain organoids, Clinicaltrials.gov change Read More »
Organoids and especially brain organoids, which are made from pluripotent stem cells, are one of the most interesting developmental biology technologies of the last half a dozen or so years. Still some folks can’t help but get carried away when thinking about brain organoids it seems. A new Science paper from a team led by
Dissecting that Neanderthal brain organoids Science pub Read More »
Approval of Prop 14 California last month to renew CIRM was one of the biggest state election developments of 2020. Yet it didn’t get much news coverage somehow. The exception is David Jensen over at California Stem Cell Report, who has been a great source of information about the various news surrounding Prop 14 and
Prop 14 California: Big Expectations for CIRM 3.0 Read More »
As a researcher, is there ever enough time to get to everything that you want to read especially in newer areas like stem cells, organoids, and CRISPR, without even including non-scientific reads like Shakespeare or a new novel or something like that? Hopefully, putting together lists of recommended reads like today’s post is helpful. I
Weekly reads on organoids, COVID, CRISPR, cold chromatin, more Read More »
Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow
Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »
It was fascinating to read a new JAMA piece by the FDA on unproven stem cell clinics and other regenerative medicine firms. Many of these guys are profiteering off of buzz about exciting, but mostly unproven technologies. While the JAMA opinion piece reiterates the agency’s commitment to evidence-based regenerative medicine, it also makes some other
Striking FDA Hahn & Marks JAMA pub on regenerative clinics Read More »